TDF HIV Drugs Lawsuit

Gilead Sciences allegedly developed a less toxic version of the TDF drug, but lawsuits will maintain they withheld it from the market.

Contact us for a free legal consultation.


TDF HIV Drugs Lawsuit

Lawsuits will maintain that Gilead withheld a less toxic HIV drug in order to maximize profits.

Our attorneys are pursuing legal action against Gilead Sciences for allegedly withholding safer HIV drugs from the market.

Gilead Sciences is the leading manufacturer of HIV drugs worldwide. They manufacture tenofovir disoproxil fumarate (TDF) antiretroviral drugs—Viread, Atripla, Complera, Stribild, and Truvada—used to treat HIV. But thousands of people living with HIV have allegedly complained of kidney and bone injuries after taking TDF drugs.

Lawsuits allege that Gilead Sciences manufactured a less toxic version of the drug, but withheld it from the market. The drug—tenofovir alafenamide fumarate (TAF), present in Odefsey, Genvoya, Descovy, Biktarvy, and Vemlidy—was allegedly tested in clinical trials in 2002, but wasn’t released until 2015.

Safer Drug Allegedly Delayed

TAF drugs allegedly could be used at one-tenth the dose of Viread, with decreased toxic side effects.

TDF-based drugs have been on the market since 2001, when the FDA approved Viread. Since then, Gilead also brought TDF drugs Truvada, Atripla, Complera, and Stribild to market.

TDF drugs have been extremely profitable for Gilead, earning them a combined $11 billion in sales in 2017 alone. They allegedly come with a number of severe side effects, like an increased risk of kidney disease and an increased risk of bone fractures.

Gilead owns 80 percent of the anti-retroviral drug market. In 2001, Gilead began development of a less toxic drug—tenofovir alafenamide fumarate (TAF). However, they allegedly slowed development in 2004.

TAF drugs allegedly could be used at a lower dose of Viread, with decreased toxic side effects.

The FDA eventually approved TAF in 2015, not long before TDF’s patent expired in 2018.

Gilead Hiked TDF Prices Prior to Patent Expiration  

Report shows that some drug price tags were hiked by 7 percent.

Shortly after TAF-based drugs Odefsey and Genvoya came on the market, Gilead raised the prices for their TDF-based drugs, Complera and Stribild, according to a report by medical news service STAT.

The prices for a month’s supply of Complera and Stribild were raised by 7 percent—up to $2,508 and $3,469, respectively. Gilead didn’t raise the prices for some of their TDF-based drugs, which remained at $2,346 and $2,578 for a month’s supply.

The timing of the price hikes raised alarms in the HIV community because they occurred just as Gilead was about to lose its exclusive hold on TDF. Since the older TDF drugs were now more expensive than TAF drugs, critics argued that it was a clear attempt to get doctors and patients to switch to the newly patented Odefsey and Genvoya, before Gilead lost business to generic competitors.

Who is Eligible for a Lawsuit Against Gilead?

TDF-based drugs allegedly have been linked to an increased risk of bone fractures.

People living with HIV who took a TDF drug—Truvada, Viread, Atripla, Complera, or Stribild—and have been diagnosed by a physician or other healthcare provider with kidney or bone injury afterwards may qualify for a lawsuit against Gilead Sciences.

Qualifying injuries include:

Kidney Injuries

  • Chronic Kidney Disease (CKD) or declining kidney function
  • Acute Kidney Injury or Acute Renal Failure
  • Fanconi’s syndrome
  • Tubular dysfunction
  • Low kidney function diagnosed by a physician or other healthcare provider
  • High creatinine levels diagnosed by a physician or other healthcare provider
  • Abnormal glomerular filtration rate (GFR) levels (15 to 90) as determined by tests and blood work
  • Renal failure and hospitalization
  • Death due to renal failure
  • Abnormal protein levels in the urine

Bone Injuries

  • Osteopenia
  • Osteoporosis
  • Bone fractures with physician or healthcare provider diagnosis of bone weakening or demineralization
  • Bone density loss, bone demineralization, or weakening of the bones diagnosed by a physician or other healthcare provider;

Why File a Lawsuit?

Filing a lawsuit may help patients recover compensation to ease the financial burdens of their injury.  A lawsuit may help to recover compensation for:

  • Medical bills
  • Loss of earnings (past and future)
  • Pain and suffering

We Want to Hold Gilead Accountable

Pharmaceutical companies like Gilead Sciences shouldn’t be allowed to put profits over the safety of thousands of Americans, especially when patients are suffering from life-threatening conditions.

Our firm stands with people living with HIV. That’s why we’re working with Ben Crump Law and Hilliard Martinez Gonzales to hold Gilead Sciences accountable for any harm they may have done.

If you took Truvada, Viread, Atripla, Complera, or Stribild and after was diagnosed by a physician or other healthcare provider with kidney or bone injury, you may be eligible for a lawsuit. Contact us to see if you have a case. It never costs a thing unless we win a settlement or verdict for you.


Did you find what you need?